Skip to main content

Table 2 Cost comparisons of current standard of care for stroke patients at BPH compared with pharmacogenetic stratification (PGx) or a randomized alternative

From: Application of personalized medicine to chronic disease: a feasibility assessment

Proportion of stroke patients treated with particular medication Average annual cost $ Base case (standard of care) PGx stratified Alternative random
ASA 27 0.5 0.5 0.5
Plavix 941 0.4 0.32 0.2
Aggrenox 601 0.1 0.1 0.1
Effient (estimated cost) 1110 0 0.08 0.2
Proportion of untreated 0.08 0.016 0.04
Recurrence risk untreated 0.2 0.2 0.2
Recurrence risk treated 0.072 0.072 0.072
Cost of treatment failure 53,576 53,576 53,576
Probability of failure 0.082 0.074 0.077
Risk adjusted failure cost* 4406 3967 4132
Incremental annual cost of treatment 450 463 484
Cost of PGx test 0 250 0
Total costs Year 1 4856 4680 4615
Discounted costs Year 2** 4714 4301 4481
Discounted costs Year 3** 4577 4176 4350
Discounted costs Year 4** 4444 4055 4224
Discounted costs Year 5** 4314 3936 4101
Cumulative costs: 22905 21149 21771
Differential savings 0 1756 1134
  1. *Average cost of ischemic stroke treatment in Ontario according to Goeree et al, 2005.
  2. Please note that the costs are substantially higher for more severe stroke patients: costs for patients with Modified Rankin Score 4 = 100,000$CDN and score 5 = 200,000$CDN.
  3. **NPV calculation assumes 3% annual interest rate.